MedTrace Logo

Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

NCT01128439 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2018-12-04

No results posted yet for this study

Summary

This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.

Conditions

  • Invasive Pneumococcal Disease

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Kaiser Permanente

    collaborator OTHER

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01128439 on ClinicalTrials.gov